Evidence mapPaperPMID 41601649Full record

ReviewFrontiers in immunology2025

Decoding inflammatory regulation in ovarian cancer at single-cell resolution.

Jianghao Yu, Tingting Zhou, Shuangyu Chen, Jialin Zhu, Lu Xu, Yibo He, Wei Chen

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jianghao Yu *The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
Tingting Zhou *The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
Shuangyu ChenThe First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
Jialin ZhuThe Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Lu XuThe First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
Yibo HeThe First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
Wei ChenThe First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer(OC) poses a significant clinical challenge due to its frequent peritoneal dissemination and development of chemotherapy resistance, contributing to poor patient outcomes. Chronic inflammation is a pivotal driver of disease initiation and progression. While traditional population-level studies fail to capture cellular heterogeneity, recent advances in single-cell technologies including scRNA-seq, spatial transcriptomics, and multi-omics, have enabled high-resolution analysis of inflammatory regulation within the ovarian cancer microenvironment(OCME). This review synthesizes how single-cell approaches have elucidated inflammation-driven remodeling of OCME components, immune cell signaling pathways, and dynamic inflammatory-immune interactions. Focusing on the "dual microenvironments" of ovarian cancer, we discuss mechanisms of immune suppression, stromal reprogramming, and therapy resistance, along with current progress and challenges in translating these insights into precise diagnostic, targeted therapeutic, and immunotherapeutic strategies.

Indexed as

InflammationOvarian NeoplasmsSingle-Cell AnalysisTumor MicroenvironmentAnimalsFemaleHumansImmunotherapySignal TransductionSingle-Cell Gene Expression Analysischronic inflammationimmunotherapyovarian cancersingle-cell technologytumor microenvironment

Identifiers

PMID41601649
PMCPMC12833326

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.